Movement Alert｜Edwards Lifesciences Rises 6.05% in Regular Trading, Q2 Earnings Beat Expectations and TAVR Guidance Raised

Market Focus07-24

On July 24, Edwards Lifesciences rose 6.05% in regular trading, trading at $87.98/share, with turnover of $38.45 million. The rally was driven by the company's Q2 results that comprehensively exceeded market expectations, coupled with an analyst upgrade.

Edwards reported Q2 adjusted EPS of $0.78, beating the consensus estimate of $0.74 by 5.41%, representing a 16.42% year-over-year increase. Revenue came in at $1.741 billion versus $1.700 billion expected, up from $1.53 billion a year earlier. Core TAVR product sales reached $1.26 billion, growing 11.3% year-over-year and surpassing the $1.23 billion estimate. The company raised its full-year TAVR sales growth guidance lower bound from 7% to 8%, while maintaining adjusted EPS guidance of $2.95 to $3.05.

Following the results, Leerink Partners upgraded Edwards to Outperform from Market Perform and raised its price target to $101 from $87, reflecting increased confidence in the company's growth trajectory.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1117790071?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-24 21:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1117790071","market":"us","top_or_hot":-1,"title":"Movement Alert｜Edwards Lifesciences Rises 6.05% in Regular Trading, Q2 Earnings Beat Expectations and TAVR Guidance Raised","media":"Market Focus","content":"<p><p>On July 24, Edwards Lifesciences rose 6.05% in regular trading, trading at $87.98/share, with turnover of $38.45 million. The rally was driven by the company's Q2 results that comprehensively exceeded market expectations, coupled with an analyst upgrade.</p><p>Edwards reported Q2 adjusted EPS of $0.78, beating the consensus estimate of $0.74 by 5.41%, representing a 16.42% year-over-year increase. Revenue came in at $1.741 billion versus $1.700 billion expected, up from $1.53 billion a year earlier. Core TAVR product sales reached $1.26 billion, growing 11.3% year-over-year and surpassing the $1.23 billion estimate. The company raised its full-year TAVR sales growth guidance lower bound from 7% to 8%, while maintaining adjusted EPS guidance of $2.95 to $3.05.</p><p>Following the results, Leerink Partners upgraded Edwards to Outperform from Market Perform and raised its price target to $101 from $87, reflecting increased confidence in the company's growth trajectory.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Edwards Lifesciences Rises 6.05% in Regular Trading, Q2 Earnings Beat Expectations and TAVR Guidance Raised</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Edwards Lifesciences Rises 6.05% in Regular Trading, Q2 Earnings Beat Expectations and TAVR Guidance Raised\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-24 21:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 24, Edwards Lifesciences rose 6.05% in regular trading, trading at $87.98/share, with turnover of $38.45 million. The rally was driven by the company's Q2 results that comprehensively exceeded market expectations, coupled with an analyst upgrade.</p><p>Edwards reported Q2 adjusted EPS of $0.78, beating the consensus estimate of $0.74 by 5.41%, representing a 16.42% year-over-year increase. Revenue came in at $1.741 billion versus $1.700 billion expected, up from $1.53 billion a year earlier. Core TAVR product sales reached $1.26 billion, growing 11.3% year-over-year and surpassing the $1.23 billion estimate. The company raised its full-year TAVR sales growth guidance lower bound from 7% to 8%, while maintaining adjusted EPS guidance of $2.95 to $3.05.</p><p>Following the results, Leerink Partners upgraded Edwards to Outperform from Market Perform and raised its price target to $101 from $87, reflecting increased confidence in the company's growth trajectory.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"EW","symbol_name":"爱德华兹","start_time":0,"source_url":"","article_id":"1117790071","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1117790071","pubTimestamp":1784900016,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 24, Edwards Lifesciences rose 6.05% in regular trading, trading at $87.98/share, with turnover of $38.45 million. The rally was driven by the company's Q2 results that comprehensively...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"EW":"爱德华兹"},"translate_title":"走势警报|Edwards Lifesciences 常规交易上涨 6.05%，第二季度盈利超出预期，TAVR 指引上调","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EW":1},"content_text":"On July 24, Edwards Lifesciences rose 6.05% in regular trading, trading at $87.98/share, with turnover of $38.45 million. The rally was driven by the company's Q2 results that comprehensively exceeded market expectations, coupled with an analyst upgrade.Edwards reported Q2 adjusted EPS of $0.78, beating the consensus estimate of $0.74 by 5.41%, representing a 16.42% year-over-year increase. Revenue came in at $1.741 billion versus $1.700 billion expected, up from $1.53 billion a year earlier. Core TAVR product sales reached $1.26 billion, growing 11.3% year-over-year and surpassing the $1.23 billion estimate. The company raised its full-year TAVR sales growth guidance lower bound from 7% to 8%, while maintaining adjusted EPS guidance of $2.95 to $3.05.Following the results, Leerink Partners upgraded Edwards to Outperform from Market Perform and raised its price target to $101 from $87, reflecting increased confidence in the company's growth trajectory.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1117790071","isCrawlerRequest":true}